News and Events

Equity Placing to raise US$1,500,000

26 October 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Tiziana Life Sciences plc

("Tiziana" or the "Company")

London, October 26, 2018 - Tiziana Life Sciences plc (AIM: TILS), a UK biotechnology company that focuses on the discovery and development...


Read more

Tiziana Announces Filing of an Amended Registration Statement with the SEC

18 October 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A...

Read more

Tiziana Life Sciences Announces that it will be presenting data from animal studies demonstrating the potential synergistic activity of Milciclib with Tyrosine Kinase Inhibitors to treat Hepatocellular Carcinoma (HCC) at the AASLD

16 October 2018

London, 16 October 2018- Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and inflammatory diseases, will present results from preclinical studies demonstrating synergistic activity of milciclib with sorafenib (NexavarR) to suppress tumor...

Read more

Tiziana Announces Launch of Offering and Application to List on the Nasdaq Capital Market

25 September 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A...

Read more

U.S. Food and Drug Administration approves application for Investigational New Drug; Phase I Clinical Study set to commence enrolment in late 2018

24 September 2018

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE...

Read more

Interim Results for the Six Months Ended 30 June 2018 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need

24 September 2018

London, 24 September 2018 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for the six months ended...

Read more

Page 1 of 3 Next

Search our news archives